FI116828B - Förfarande för framställning av en antikropp som är immunoreaktiv med ett CD40-L-protein - Google Patents

Förfarande för framställning av en antikropp som är immunoreaktiv med ett CD40-L-protein Download PDF

Info

Publication number
FI116828B
FI116828B FI981765A FI981765A FI116828B FI 116828 B FI116828 B FI 116828B FI 981765 A FI981765 A FI 981765A FI 981765 A FI981765 A FI 981765A FI 116828 B FI116828 B FI 116828B
Authority
FI
Finland
Prior art keywords
protein
cells
leu
ser
val
Prior art date
Application number
FI981765A
Other languages
English (en)
Finnish (fi)
Other versions
FI981765A (sv
FI981765A0 (sv
Inventor
Richard J Armitage
William C Fanslow
Melanie K Spriggs
Subhashini Srinivasan
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27120174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI116828(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of FI981765A publication Critical patent/FI981765A/sv
Publication of FI981765A0 publication Critical patent/FI981765A0/sv
Application granted granted Critical
Publication of FI116828B publication Critical patent/FI116828B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (4)

1. Förfarande för framställning av en a som är immunoreaktiv med ett humant CD40-L-protein 5 netecknatav att ett djur, mänskan undanta muniseras med nämnda CD40-L-protein eller ett im fragment därav, och antikroppar som reagerar däi tillvara antigen direkt frän djuret eller frän et dom som framställts genom att fusionera mjaltcel! 10 nämnda djur med myelomceller, varvid CD40-L är en tid som definieras av aminosyrorna 1 - 261 i sekve ID nummer 12, nämnda aminosyror inberäknade.
2. Förfarande enligt patentkrav 1, kä n n < tecknatavatt man framställer en monoklon 15 kropp.
3. Förfarande för framställning av en a som är immunoreaktiv med ett CD40-L-protein frän m< kännetecknatav att ett djur, mänskan gen, immuniseras med nämnda CD40-L-protein eller e 20 nogent fragment därav, och antikroppar som reagera . tas tillvara antigen direkt frän djuret eller frän • · « **V bridom som framställts genom att fusionera mjä * * * ’;*·* frän nämnda djur med myelomceller, varvid CD40-L ä * φ * ** lypeptid som definieras av aminosyrorna 1 - 260 i * * 25 sen SEQ ID nummer 2, nämnda aminosyror inberäknade
4. Förfarande enligt patentkrav 3, kä n n e Ml V 5 t e c k n a t av att man framställer en monoklon; kropp. ♦ · # · « • · · M· · II» • « • I ···
FI981765A 1991-10-25 1998-08-17 Förfarande för framställning av en antikropp som är immunoreaktiv med ett CD40-L-protein FI116828B (sv)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US78370791A 1991-10-25 1991-10-25
US78370791 1991-10-25
US80572391A 1991-12-05 1991-12-05
US80572391 1991-12-05
US9208990 1992-10-23
PCT/US1992/008990 WO1993008207A1 (en) 1991-10-25 1992-10-23 Novel cytokine

Publications (3)

Publication Number Publication Date
FI981765A FI981765A (sv) 1998-08-17
FI981765A0 FI981765A0 (sv) 1998-08-17
FI116828B true FI116828B (sv) 2006-03-15

Family

ID=27120174

Family Applications (2)

Application Number Title Priority Date Filing Date
FI941837A FI116850B (sv) 1991-10-25 1994-04-20 Nukleinsyror som kodar CD40-L-polypeptider och användning av dessa
FI981765A FI116828B (sv) 1991-10-25 1998-08-17 Förfarande för framställning av en antikropp som är immunoreaktiv med ett CD40-L-protein

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FI941837A FI116850B (sv) 1991-10-25 1994-04-20 Nukleinsyror som kodar CD40-L-polypeptider och användning av dessa

Country Status (13)

Country Link
EP (2) EP0667901B2 (sv)
JP (2) JP3308534B2 (sv)
KR (1) KR100283541B1 (sv)
AT (2) ATE239790T1 (sv)
AU (1) AU661360B2 (sv)
CA (2) CA2121798C (sv)
DE (2) DE69233402T3 (sv)
DK (3) DK0667901T4 (sv)
ES (2) ES2227513T5 (sv)
FI (2) FI116850B (sv)
HK (1) HK1019343A1 (sv)
NO (2) NO317625B1 (sv)
WO (1) WO1993008207A1 (sv)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981724A (en) * 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US7070777B1 (en) * 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US6472510B1 (en) 1992-02-14 2002-10-29 Bristol-Myers Squibb Company CD40 receptor ligands
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
AU5098493A (en) * 1992-08-21 1994-03-15 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
EP0612529B1 (en) * 1993-01-22 2000-04-05 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Therapeutic agent for NIDDM
ES2211876T3 (es) * 1993-01-22 2004-07-16 Immunex Corporation Deteccion y tratamiento de mutaciones en un gel del ligando de cd40.
JP2840131B2 (ja) * 1993-09-02 1998-12-24 トラスティーズ・オブ・ダートマス・カレッジ 液性免疫の持続性抑制方法
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
ZA946765B (en) * 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
CN100341896C (zh) 1993-09-02 2007-10-10 达特茅斯学院理事 抗gp39抗体及其应用
AU1059095A (en) * 1993-11-24 1995-06-13 Australian National University, The Treatment of viral disease with cd40l peptide
JPH09507074A (ja) * 1993-12-23 1997-07-15 イミュネックス・コーポレーション Ｃｄ４０を発現する腫瘍細胞を特徴とする疾患の予防又は治療方法
US5683693A (en) 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
EP0763057B1 (en) 1994-04-28 2005-11-09 Boehringer Ingelheim Pharmaceuticals Inc. Method for proliferating and differentiating b cells, and uses thereof
ES2179187T3 (es) * 1995-03-01 2003-01-16 Immunex Corp Oriteuba qye se yba a cd40 para estimular una respuesta inmune.
AU2556195A (en) 1995-03-13 1996-10-02 Regents Of The University Of Michigan, The CD40 binding compositions and methods of using same
WO1996040918A2 (en) * 1995-06-07 1996-12-19 Immunex Corporation Novel cd40l mutein
DK0833847T3 (da) * 1995-06-22 2003-12-29 Biogen Inc Krystaller af fregmenter af CD40-ligand og deres anvendelse
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
DE69728269T2 (de) * 1996-06-14 2005-03-10 University Of Washington, Seattle Absorbtionsverbessertes differentielles extraktionsverfahren
AU705647B2 (en) * 1996-07-10 1999-05-27 Immunex Corporation Method of activating dendritic cells
US6017527A (en) * 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
JP2002509431A (ja) 1996-12-23 2002-03-26 イミュネックス・コーポレーション ＮＦ−κＢのレセプター活性化因子−レセプターはＴＮＦレセプタースーパーファミリーの一員である−
EP2009025B1 (en) 1998-05-14 2011-07-27 Immunex Corporation Method of inhibiting osteoclast activity
AU773891C (en) * 1998-10-23 2005-02-17 Kirin-Amgen Inc. Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
EP1067194A1 (en) * 1999-04-16 2001-01-10 F. Hoffmann-La Roche Ag Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
IL144952A0 (en) * 1999-04-16 2002-06-30 Hoffmann La Roche Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
WO2001016180A2 (en) * 1999-08-27 2001-03-08 Board Of Regents, The University Of Texas System Cd40 agonist compositions and methods of use
GB9927757D0 (en) * 1999-11-25 2000-01-26 Kennedy Rheumatology Inst Treatment of autoimmune diseases
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
AU2001261585B2 (en) 2000-05-12 2006-08-31 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
AU2001296507A1 (en) 2000-10-02 2002-04-15 Chiron Corporation Human anti-cd40 antibodies
AU2002221780A1 (en) * 2000-10-31 2002-05-15 F.Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US6586245B2 (en) 2001-07-18 2003-07-01 Isis Pharmaceuticals, Inc. Antisense modulation of CD40 ligand expression
WO2003011324A1 (en) * 2001-07-31 2003-02-13 Genset S.A. Agonists and antagonists of moxifin for the treatment of metabolic disorders
PT1434871T (pt) 2001-09-20 2017-04-05 Immunex Corp Seleção de células que expressam polipéptidos heteroméricos
US7786282B2 (en) 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
RS20050614A (en) 2003-02-14 2007-12-31 Biogen Idec Ma Inc., An expression cassette and vector for transient or stable expression of exogenous molecules
CN101072587B (zh) 2004-07-26 2012-12-26 比奥根艾迪克Ma公司 抗-cd154抗体
US8513008B2 (en) * 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
JP5269412B2 (ja) 2004-10-07 2013-08-21 アルゴス セラピューティクス，インコーポレイティド 成熟樹状細胞組成物およびその培養方法
KR101370253B1 (ko) 2004-10-22 2014-03-05 암젠 인크 재조합 항체의 재접힘 방법
SG10201510384UA (en) 2006-09-13 2016-01-28 Abbvie Inc Cell culture improvements
EP2500415A1 (en) 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
PL2066339T3 (pl) 2006-09-18 2015-02-27 Univ Arkansas Kompozycje i sposoby zwiększania odpowiedzi immunologicznych
US20100226925A1 (en) 2007-09-14 2010-09-09 Amgen Inc. Homogeneous Antibody Populations
NZ585776A (en) 2007-10-30 2012-07-27 Univ Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
CA3051748C (en) 2007-11-01 2022-07-12 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to eimeria
WO2009091912A2 (en) 2008-01-15 2009-07-23 Abbott Laboratories Improved mammalian expression vectors and uses thereof
DK2501822T3 (da) 2009-11-17 2017-11-27 Squibb & Sons Llc Fremgangsmåder til forbedret proteinproduktion
MX341775B (es) 2010-01-21 2016-09-02 The Texas A&M Univ System * Vectores para vacunas y metodos para potenciar respuestas inmunes.
KR102008120B1 (ko) 2010-06-09 2019-08-07 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 캄필로박터 감염을 감소시키기 위한 백신 및 방법
HUE047484T2 (hu) 2013-02-14 2020-04-28 Univ Arkansas Készítmények és eljárások eimeria elleni immunválasz fokozására vagy eimeria-fertõzés korlátozására
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
JP6530742B2 (ja) 2013-03-15 2019-06-12 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 腸内病原体の免疫応答を強化する組成物及び方法
AU2016291817A1 (en) 2015-07-16 2018-02-22 Biolinerx Ltd. Compositions and methods for treating cancer
MX2018001522A (es) 2015-08-05 2018-03-15 Janssen Biotech Inc Anticuerpos anti-cd154 y metodos de uso de estos.
WO2017083604A1 (en) 2015-11-12 2017-05-18 Amgen Inc. Triazine mediated pharmacokinetic enhancement of therapeutics
TWI843057B (zh) 2016-05-03 2024-05-21 阿肯色州大學董事會 包含免疫刺激性及抗原性多肽的酵母菌疫苗載體以及其使用方法
TWI821905B (zh) 2016-05-11 2023-11-11 美商安美基公司 使用麩醯胺合成酶基因內互補載體直接選擇表現高水準異質蛋白的細胞
CA3054132A1 (en) * 2017-02-27 2018-08-30 Shattuck Labs, Inc. Csf1r-based chimeric proteins
EP3585418A4 (en) 2017-02-27 2020-11-25 Shattuck Labs, Inc. TIGITE AND LIGHT BASED CHIMERIC PROTEINS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2089229C (en) * 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation

Also Published As

Publication number Publication date
ATE274055T1 (de) 2004-09-15
DK0897983T3 (da) 2003-08-11
FI116850B (sv) 2006-03-15
EP0667901B2 (en) 2008-10-15
CA2312667C (en) 2002-11-19
JP2877788B2 (ja) 1999-03-31
AU661360B2 (en) 1995-07-20
DE69233402D1 (de) 2004-09-23
NO941422D0 (no) 1994-04-19
ATE239790T1 (de) 2003-05-15
NO941422L (sv) 1994-06-27
EP0667901B1 (en) 2004-08-18
EP0897983A3 (en) 1999-03-17
ES2227513T3 (es) 2005-04-01
FI941837A (sv) 1994-05-30
JPH07504083A (ja) 1995-05-11
KR100283541B1 (ko) 2001-03-02
CA2121798A1 (en) 1993-04-29
FI981765A (sv) 1998-08-17
ES2198025T3 (es) 2004-01-16
NO320073B1 (no) 2005-10-17
FI981765A0 (sv) 1998-08-17
EP0667901A4 (en) 1995-06-22
NO317625B1 (no) 2004-11-29
JPH10150994A (ja) 1998-06-09
AU3122693A (en) 1993-05-21
CA2312667A1 (en) 1993-04-29
DK0822199T3 (da) 2004-12-27
DE69233402T3 (de) 2009-06-25
WO1993008207A1 (en) 1993-04-29
DE69233402T2 (de) 2005-09-15
CA2121798C (en) 2007-07-24
DE69233051D1 (de) 2003-06-12
FI941837A0 (sv) 1994-04-20
NO980030D0 (no) 1998-01-05
EP0897983B1 (en) 2003-05-07
HK1019343A1 (en) 2000-02-03
NO980030L (no) 1998-01-05
DE69233051T2 (de) 2004-03-11
EP0897983A2 (en) 1999-02-24
ES2227513T5 (es) 2009-04-01
DK0667901T3 (da) 2004-12-27
EP0667901A1 (en) 1995-08-23
JP3308534B2 (ja) 2002-07-29
DK0667901T4 (da) 2008-11-10

Similar Documents

Publication Publication Date Title
FI116828B (sv) Förfarande för framställning av en antikropp som är immunoreaktiv med ett CD40-L-protein
US6264951B1 (en) Methods of inhibiting CD40L binding to CD40 with soluble monomeric CD40L
US6290972B1 (en) Method of augmenting a vaccine response by administering CD40 ligand
US5961974A (en) Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
AU693713B2 (en) CD40L mutein
EP0817847B2 (en) Il-17 receptor
Ziegler et al. Molecular characterization of the early activation antigen CD69: a type II membrane glycoprotein related to a family of natural killer cell activation antigens
US5783665A (en) Cytokine which is a ligand for OX40
MXPA97009447A (en) New muteina cd
US20040006006A9 (en) CD40-Ligand lacking native-pattern glycosylation
FI103987B (sv) Interleukin-7
US5726036A (en) Granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
US5629283A (en) Granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
ES et al. NEUE CYTOKINE NOUVELLE CYTOKINE

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 116828

Country of ref document: FI

MA Patent expired